HilleVax
A biopharmaceutical company developing and commercializing novel vaccines.
The company's initial program, HIL-214, is a virus-like particle based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infect.
Latest HilleVax News & Features
12 January 2024
30 July 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze